Moderna, Inc. (NASDAQ:MRNA) Receives $67.26 Average PT from Analysts

Moderna, Inc. (NASDAQ:MRNA) has been given a consensus recommendation of “Hold” by the twenty-three brokerages that are presently covering the company, MarketBeat reports. Four equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $67.26.

A number of equities research analysts have weighed in on the company. Argus lowered Moderna from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Evercore ISI decreased their price objective on shares of Moderna from $60.00 to $50.00 and set an “in-line” rating on the stock in a research report on Monday, January 27th. Piper Sandler reissued an “overweight” rating and set a $69.00 price target (down previously from $115.00) on shares of Moderna in a research report on Monday, November 18th. Hsbc Global Res raised shares of Moderna from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 18th. Finally, Needham & Company LLC restated a “hold” rating on shares of Moderna in a report on Friday, November 8th.

Moderna Stock Down 7.3 %

Shares of NASDAQ:MRNA opened at $36.55 on Friday. The firm has a 50 day simple moving average of $40.89 and a 200-day simple moving average of $60.43. Moderna has a twelve month low of $31.94 and a twelve month high of $170.47. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $14.07 billion, a PE ratio of -6.28 and a beta of 1.60.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The firm had revenue of $1.90 billion during the quarter, compared to analysts’ expectations of $1.25 billion. During the same quarter in the prior year, the business earned ($1.39) EPS. Moderna’s quarterly revenue was up 3.8% compared to the same quarter last year. On average, equities analysts predict that Moderna will post -9.18 EPS for the current fiscal year.

Insider Buying and Selling

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of the stock in a transaction on Friday, November 29th. The shares were sold at an average price of $42.79, for a total transaction of $60,676.22. Following the sale, the insider now directly owns 19,717 shares of the company’s stock, valued at approximately $843,690.43. This represents a 6.71 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Over the last 90 days, insiders have sold 2,664 shares of company stock worth $115,210. 15.70% of the stock is currently owned by corporate insiders.

Institutional Trading of Moderna

Several hedge funds have recently made changes to their positions in the stock. Axiom Advisory LLC raised its holdings in shares of Moderna by 1.6% during the 3rd quarter. Axiom Advisory LLC now owns 12,672 shares of the company’s stock valued at $847,000 after purchasing an additional 198 shares in the last quarter. Arkadios Wealth Advisors lifted its position in Moderna by 2.2% during the 3rd quarter. Arkadios Wealth Advisors now owns 11,429 shares of the company’s stock worth $764,000 after acquiring an additional 243 shares during the last quarter. Knuff & Co LLC grew its holdings in Moderna by 5.4% in the 3rd quarter. Knuff & Co LLC now owns 4,732 shares of the company’s stock valued at $316,000 after buying an additional 244 shares during the last quarter. Stephens Inc. AR increased its position in Moderna by 7.9% during the third quarter. Stephens Inc. AR now owns 3,334 shares of the company’s stock worth $223,000 after acquiring an additional 245 shares during the period. Finally, Mather Group LLC. grew its position in Moderna by 25.7% during the third quarter. Mather Group LLC. now owns 1,281 shares of the company’s stock worth $86,000 after buying an additional 262 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.